Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Elevar Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe. These rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, Iceland).
Product Name : Apealea
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
December 28, 2020
Lead Product(s) : Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Elevar Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ocriplasmin
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Oxurion
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®
Details : The Agreement with Inceptua will allow Oxurion to focus fully on further advancing its promising next-generation therapeutic pipeline of non-VEGF products for the treatment of diabetic eye disease.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
March 13, 2020
Lead Product(s) : Ocriplasmin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Oxurion
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
